Pulmonary hypertension classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (15 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pulmonary hypertension}} | {{Pulmonary hypertension}} | ||
{{CMG}}, Richard Channick, M.D.; '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]]; Lisa Prior, [[Ann Slater|Ann Slater, R.N.]]; {{Rim}} | {{CMG}}, Richard Channick, M.D.; '''Assistant Editor(s)-in-Chief:''' [[User:Ralph Matar|Ralph Matar]]; Lisa Prior, [[Ann Slater|Ann Slater, R.N.]]; {{Rim}}; {{Jose}} | ||
==Overview== | ==Overview== | ||
[[Pulmonary hypertension]] may be classified according to the mechanism leading to its development into 5 groups: [[pulmonary arterial hypertension]], [[pulmonary hypertension due to left heart disease]], [[pulmonary hypertension due to chronic lung diseases and/or hypoxia]], and [[pulmonary hypertension due to embolic disease]], and [[miscellaneous]] causes. | |||
Pulmonary hypertension | ==Classification== | ||
*[[Pulmonary hypertension]] was first classified into [[primary]] and [[secondary]] in 1973 during the [[World Health Organization]] (WHO) meeting on PH in Geneva, Switzerland.<ref name="WHO1973">Hatano S, Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. October 15–17, 1973, Geneva: World Health Organization, 1975.</ref> | |||
*Pulmonary hypertension can be classified following different methods such as using the [[WHO]] clinical criteria, the hemodynamic findings, and the histopathological findings. The most common method of classification is using the disease mechanism, established by the World Health Organization, which is discussed below in detail. | |||
== | ==WHO - Clinical Classification== | ||
* [[Pulmonary hypertension]] was first classified into [[primary]] and [[secondary]] in 1973 during the [[World Health Organization]] (WHO) meeting on PH in Geneva, Switzerland.<ref name="WHO1973">Hatano S, Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. October 15–17, 1973, Geneva: World Health Organization, 1975.</ref> | |||
* | * The classification of the disease has been progressively updated since then and the latest version was defined in 2018, during the 6th World Symposium on Pulmonary Hypertension. | ||
* It is currently used by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the labeling of new drugs approved for the treatment of [[pulmonary hypertension]]. | |||
* The | *The latest classification method categorizes [[pulmonary hypertension]] into 5 groups: | ||
** | ** Group I - Pulmonary arterial hypertension | ||
** | ** Group II - Pulmonary hypertension due to left heart disease | ||
** | ** Group III - Pulmonary hypertension due to chronic lung diseases and/or hypoxia | ||
** Group IV - Pulmonary hypertension due to embolic disease | |||
** Group V - Miscellaneous causes (e.g., sarcoidosis, lymphatic obstruction) | |||
===WHO Classification=== | |||
Shown below is a table with the detailed classification of [[pulmonary hypertension]].<ref name="pmid24355639">{{cite journal| author=Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al.| title=Updated clinical classification of pulmonary hypertension. | journal=J Am Coll Cardiol | year= 2013 | volume= 62 | issue= 25 Suppl | pages= D34-41 | pmid=24355639 | doi=10.1016/j.jacc.2013.10.029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24355639 }} </ref> | |||
Shown below is a table | |||
<span style="font-size: 80%;">''Abbreviations:'' BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.</span> | <span style="font-size: 80%;">''Abbreviations:'' BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.</span> | ||
| Line 108: | Line 113: | ||
|} | |} | ||
==Classification Based on Hemodynamical Findings== | |||
<span style="font-size: 80%;">'''Abbreviations:''' '''PAP:''' Pulmonary artery pressure; '''PWP:''' pulmonary wedge pressure </span> | <span style="font-size: 80%;">'''Abbreviations:''' '''PAP:''' Pulmonary artery pressure; '''PWP:''' pulmonary wedge pressure </span> | ||
| Line 148: | Line 126: | ||
|} | |} | ||
PH is a pathological condition present in different disease states that share similar clinical | ==Classification Based on Histopathological Findings== | ||
PH is a pathological condition present in different disease states that share similar clinical manifestations and some common histopathological features. Shown below is a table that summarizes the classification of PH based on histopathology findings.<ref name="pmid15194175">{{cite journal| author=Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM et al.| title=Pathologic assessment of vasculopathies in pulmonary hypertension. | journal=J Am Coll Cardiol | year= 2004 | volume= 43 | issue= 12 Suppl S | pages= 25S-32S | pmid=15194175 | doi=10.1016/j.jacc.2004.02.033 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15194175 }} </ref> | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
|- | |- | ||
Latest revision as of 13:34, 9 June 2021
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension classification On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension classification |
|
Risk calculators and risk factors for Pulmonary hypertension classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Richard Channick, M.D.; Assistant Editor(s)-in-Chief: Ralph Matar; Lisa Prior, Ann Slater, R.N.; Rim Halaby, M.D. [2]; José Eduardo Riceto Loyola Junior, M.D.[3]
Overview
Pulmonary hypertension may be classified according to the mechanism leading to its development into 5 groups: pulmonary arterial hypertension, pulmonary hypertension due to left heart disease, pulmonary hypertension due to chronic lung diseases and/or hypoxia, and pulmonary hypertension due to embolic disease, and miscellaneous causes.
Classification
- Pulmonary hypertension was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland.[1]
- Pulmonary hypertension can be classified following different methods such as using the WHO clinical criteria, the hemodynamic findings, and the histopathological findings. The most common method of classification is using the disease mechanism, established by the World Health Organization, which is discussed below in detail.
WHO - Clinical Classification
- Pulmonary hypertension was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland.[1]
- The classification of the disease has been progressively updated since then and the latest version was defined in 2018, during the 6th World Symposium on Pulmonary Hypertension.
- It is currently used by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the labeling of new drugs approved for the treatment of pulmonary hypertension.
- The latest classification method categorizes pulmonary hypertension into 5 groups:
- Group I - Pulmonary arterial hypertension
- Group II - Pulmonary hypertension due to left heart disease
- Group III - Pulmonary hypertension due to chronic lung diseases and/or hypoxia
- Group IV - Pulmonary hypertension due to embolic disease
- Group V - Miscellaneous causes (e.g., sarcoidosis, lymphatic obstruction)
WHO Classification
Shown below is a table with the detailed classification of pulmonary hypertension.[2]
Abbreviations: BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.
| Group 1. Pulmonary arterial hypertension (PAH) |
| 1.1. Idiopathic PAH |
| 1.2. Heritable PAH 1.2.1 BMPR2 |
| 1.3 Drug and toxin-induced Definite (an epidemic or large multicenter epidemiological studies demonstrating an association between a drug and PAH) Likely (a single case-control study demonstrating an association or a multiple-case series) Possible (drugs with similar mechanisms of action as those in the definite or likely category but which have not yet been studied)
Unlikely (one in which a drug has been studied in epidemiological studies and an association with PAH has not been demonstrated) |
| 1.4 Associated with: 1.4.1 Connective tissue disease |
| 1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) |
| 1’’ Persistent pulmonary hypertension of the newborn (PPHN) |
| Group 2. Pulmonary hypertension due to left heart disease |
| 2.1 Left ventricular systolic dysfunction |
| 2.2 Left ventricular diastolic dysfunction |
| 2.3 Valvular disease |
| 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies |
| Group 3. Pulmonary hypertension due to lung diseases and/or hypoxia |
| 3.1 Chronic obstructive pulmonary disease |
| 3.2 Interstitial lung disease |
| 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern |
| 3.4 Sleep-disordered breathing |
| 3.5 Alveolar hypoventilation disorders |
| 3.6 Chronic exposure to high altitude |
| 3.7 Developmental lung diseases |
| Group 4. Chronic thromboembolic pulmonary hypertension (CTEPH) |
| Group 5. Pulmonary hypertension with unclear multifactorial mechanisms |
| 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy |
| 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis |
| 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders |
| 5.4 Others: tumor obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH |
Classification Based on Hemodynamical Findings
Abbreviations: PAP: Pulmonary artery pressure; PWP: pulmonary wedge pressure
| Type of pulmonary hypertension | Possible clinical class | Mean PAP | PWP |
| Pre-capillary | Class I Class III Class IV Class V |
≥ 25 mmHg | ≤ 15 mmHg |
| Post-capillary | Class II | ≥ 25 mmHg | > 15 mmHg |
Classification Based on Histopathological Findings
PH is a pathological condition present in different disease states that share similar clinical manifestations and some common histopathological features. Shown below is a table that summarizes the classification of PH based on histopathology findings.[3]
| Class | Histopathological findings[3] |
| Pulmonary arteriopathy | Constrictive lesions in pulmonary arteries:
Complex lesions in pulmonary arteries:
|
| Pulmonary arteriopathy with venous-venular changes | Changes similar to pulmonary arteriopathy PLUS Changes in venules and veins |
| Pulmonary occlusive venopathy (with or without arteriopathy) |
Changes in venules and veins:
Changes in the capillaries:
Changes in the interstitium |
| Pulmonary microvasculopathy (with or without arteriopathy and/on venopathy) |
Changes in the capillaries:
Changes in the interstitium |
| Unclassified | Non specific changes |
References
- ↑ 1.0 1.1 Hatano S, Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. October 15–17, 1973, Geneva: World Health Organization, 1975.
- ↑ Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A; et al. (2013). "Updated clinical classification of pulmonary hypertension". J Am Coll Cardiol. 62 (25 Suppl): D34–41. doi:10.1016/j.jacc.2013.10.029. PMID 24355639.
- ↑ 3.0 3.1 Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM; et al. (2004). "Pathologic assessment of vasculopathies in pulmonary hypertension". J Am Coll Cardiol. 43 (12 Suppl S): 25S–32S. doi:10.1016/j.jacc.2004.02.033. PMID 15194175.